Specific binding molecules

The present invention relates to a specific binding molecule, such as a T cell receptor (TCR), that binds to the HLA-A * 02 restrictive peptide KVLEYVIKV (SEQ ID NO: 1) derived from the cancer germline antigen MAGEA1. The specific binding molecule may comprise a non-natural mutation within the alpha and/or beta variable domain relative to the native MAGEA1TCR. The specific binding molecules of the invention are particularly suitable for use as novel immunotherapeutic agents for the treatment of malignant diseases. 本发明涉及与来源于癌种系抗原MAGEA1的HLA-A*02限制性肽KVLEYVIKV(SEQ ID NO:1)结合的特异性结合分子，例如T细胞受体(TCR)。相对于天然MAGEA1TCR，所述特异性结合分子可以包含α和/或β可变结构域内的非天然突变。本发明的特异性结合分子特别适合用作用于治疗恶性疾病的新型免疫治疗试剂。